Clinical abstract focuses on value of PURE EP™’s and its groundbreaking High Frequency Algorithm (HFA) during pulmonary vein isolation Westport, CT, Dec. 06, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization […]
Other News
Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)
Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today […]
Enzyvant Announces Merger with Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology CARY, N.C., Dec. 06, 2022 (GLOBE NEWSWIRE) — Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of Sumitovant Biopharma Ltd., today announced a merger to form a biopharmaceutical […]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Alexander (Bo) Cumbo; Chief Administrative […]
Cleerly Hires Udo Hoffmann, MD, MPH as Chief Scientific Officer
Cardiovascular clinical trial expert brings AI imaging experience to lead research efforts NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced it has appointed Udo Hoffmann, MD, MPH, as chief scientific officer. In this role, Dr. Hoffmann will oversee Cleerly’s large-scale research efforts, including […]
Limflow Appoints Mike Mathias as Vice President, Commercial Operations
PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Mike Mathias as Vice President of Commercial Operations. Mr. Mathias has spent his 30-year career successfully leading sales organizations […]
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
Approval marks second clinical trial approved by FDA this year for Company’s NK1R+ MSC platform Allogeneic CardiALLO therapy for heart failure to complement autologous cell therapy currently enrolling in Phase III CardiAMP Heart Failure clinical trial SUNNYVALE, Calif.–(BUSINESS WIRE)–BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment […]
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
– Primary Endpoint, Change in PVR at Week 24, Met with P-Value of 0.0310 – – Secondary Endpoint, Change in 6MWD, Numerically Favored Seralutinib – – Statistically Significant Improvements Observed in NT-proBNP and ECHO Measures of Cardiac Structure and Function – – Consistently Positive Results Seen Across Pre-Specified Sub-Groups, Including […]
First Patients in the World Treated with Impella RP Flex with SmartAssist
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their […]
Medtronic completes enrollment in pivotal trial evaluating first-of-its-kind pulsed field ablation catheter for patients with atrial fibrillation
SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN, Dec. 5, 2022 /PRNewswire/ — Medtronic (NYSE:MDT) today announced the completion of enrollment and final treatment in the SPHERE Per-AF Trial, a U.S. Food and Drug Administration (FDA) […]



